Highlights Kymera Therapeutics, Inc.

Stocks

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 09/06/2026 BST			5-day change	1st Jan Change
76.91 ^USD	+4.00%		+7.88%	-1.16%

06-09	Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial	MT
06-08	Kymera Therapeutics, Inc. Announces Executive Changes	CI

Highlights

06-08	Kymera Therapeutics Presents New Preclinical Data for Kt-579, Oral Irf5 Degrader, At Eular and Focis Congresses	CI
05-15	Kymera Therapeutics, Inc. Announces Presentations And Clinical Data For KT-621 Oral STAT6 Degrader	CI
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI
04-30	Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises	MT
04-30	Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss	MT
04-30	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M	MT
04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI
03-28	Kymera Therapeutics Presents KT-621 BroADen Data In Late-Breaking Research Session At The American Academy Of Dermatology Annual Meeting	CI
02-26	Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	Kymera Therapeutics Q4 Loss Widens, Revenue Falls	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Net Loss $0.97 a Share, vs. FactSet Est of $0.78 Loss	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q4 Revenue $2.9M	MT
02-26	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q4 Revenue $2.9M	MT
01-29	Kymera Therapeutics Announces First Patient Dosed in Breadth Phase 2B Asthma Clinical Trial of KT-621	CI
01-13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs	CI
12-11	Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis	MT
12-11	The U.S. Food and Drug Administration Has Granted Fast Track Designation to Kt-621, Its First-In-Class, Oral Stat6 Degrader	CI
12-10	Kymera Therapeutics announces pricing of upsized $602 million public offering at $86 per share	RE
12-08	Kymera Therapeutics Launches Public Offering of Common Shares	MT
12-08	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis	CI
12-05	Kymera Therapeutics, Inc. to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	CI
11-25	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader	CI